Skip to main content
OpenTrials
Completed

NCT Number: NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Bahía Blanca, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 85 years
  • History of, or at high risk for, cardiovascular disease (CVD) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event
  • Participant-reported SI due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued resulting in an inability to tolerate:
  • 2 or more statins at any dose, or
  • 1 statin at any dose and unwilling to attempt a second statin or advised by a physician to not attempt a second statin.

Please note that participants currently tolerating very low dose statin therapy (an average daily dose of rosuvastatin <5 mg, atorvastatin <10 mg, simvastatin <10 mg, lovastatin <20 mg, pravastatin <40 mg, fluvastatin <40 mg, or pitavastatin <2 mg) are considered to be intolerant to that low dose statin. Patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least 4 weeks prior to screening) and well tolerated.

  • Written confirmation by both participant and investigator that the participant is statin intolerant as defined above, aware of the benefit of statin use to reduce the risk of MACE including death, and also aware that many other participants who are unable to tolerate a statin are able to tolerate a different statin or dose.
  • Men and nonpregnant, nonlactating women
  • Fasting blood LDL-cholesterol ≥ 100 (2.6 mmol/L) at screening

Exclusion criteria

  • Fasting blood triglycerides greater than 500 mg/dL (5.6 mmol/L) at screening
  • Recent (within 90 days of screening) history of major cardiovascular events, transient ischemic attack (TIA), or unstable or symptomatic cardiac arrhythmia
  • History of severe heart failure
  • Uncontrolled hypertension or uncontrolled diabetes

Treatment and study plan

Bempedoic acid 180 mg tablet

Drug

Patients take bempedoic acid 180 mg tablet orally once daily

Other names: ETC-1002

Matching placebo tablet

Drug

Patients take matching placebo tablet orally once daily

Other names: placebo comparator

Primary outcomes

  1. Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)

    Time frame: Up to 68 months

    The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.

Secondary outcomes

  1. Number of Participants With First Occurrence of Three Component MACE

    Time frame: Up to 68 months

    The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

  2. Number of Participants With First Occurrence of Myocardial Infarction

    Time frame: Up to 68 months

    Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.

  3. Number of Participants With Time to First Occurrence of Coronary Revascularization

    Time frame: Up to 68 months

    Number of participants with time to first occurrence of coronary revascularization are presented.

  4. Number of Participants With Time to First Occurrence of Stroke

    Time frame: Up to 68 months

    Number of participants with time to first occurrence of fatal and non-fatal stroke.

  5. Number of Participants With Time to Cardiovascular Death

    Time frame: Up to 68 months

    Number of participants with time to cardiovascular death are presented.

  6. Number of Participants With Time to All-cause Mortality

    Time frame: Up to 68 months

    All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.

Sponsors and collaborators

Lead sponsor

Esperion Therapeutics, Inc.

Industry

Collaborators

  • The Cleveland Clinic

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Acronym: CLEAR Outcomes

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Dec 15, 2016
Registry last updated
Jan 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.